Glycine


Baxter Healthcare Corporation
Human Prescription Drug
NDC 0338-0289
Glycine is a human prescription drug labeled by 'Baxter Healthcare Corporation'. National Drug Code (NDC) number for Glycine is 0338-0289. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Glycine drug includes Glycine - 1.5 g/100mL . The currest status of Glycine drug is Active.

Drug Information:

Drug NDC: 0338-0289
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Glycine
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Glycine
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Baxter Healthcare Corporation
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:GLYCINE - 1.5 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:IRRIGATION
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 30 May, 1980
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA017865
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Baxter Healthcare Corporation
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:310571
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:TE7660XO1C
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0338-0289-473000 mL in 1 BAG (0338-0289-47)30 May, 1980N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Glycine glycine glycine glycine water

Indications and Usage:

Indications and usage 1.5% glycine irrigation, usp is indicated for use as a urologic irrigating fluid with endoscopic instruments during transurethral procedures requiring distension, irrigation, and lavage of the urinary bladder. it may be used for lavage of an indwelling catheter to maintain patency.

Warnings:

Warnings not for injection. solutions for urologic irrigation must be used with caution in patients with severe cardiopulmonary or renal dysfunction. irrigating fluids used during transurethral prostatectomy have been demonstrated to enter the systemic circulation in relatively large volumes; thus 1.5% glycine irrigation, usp must be regarded as a systemic drug. absorption of large amounts of fluids containing glycine may significantly alter cardiopulmonary and renal dynamics. careful cardiovascular monitoring should be maintained due to the possibility of fluid overload. should fluid overload occur, intensive fluid and electrolyte management is necessary. monitoring of fluid and electrolyte levels beyond the acute phase may be considered due to the possibility of delayed fluid absorption. (see adverse reactions, post-marketing experience). the contents of an opened container should be used promptly to minimize the possibility of bacterial growth or pyrogen formation. discard the unuse
d portion of irrigating solution since no antimicrobial agent has been added.

Dosage and Administration:

Dosage and administration the volume of solution needed will vary with the nature and duration of the urologic procedure. if desired, warm in overwrap to near body temperature in a water bath or oven heated to not more than 45°c. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Contraindications:

Contraindications anuria.

Adverse Reactions:

Adverse reactions adverse reactions may result from intravascular absorption of glycine. large intravenous doses of glycine are known to cause salivation, nausea and lightheadedness. other consequences of absorption of urologic irrigating solutions include fluid and electrolyte disturbances such as acidosis, electrolyte loss, marked diuresis, urinary retention, edema, dryness of mouth, thirst, dehydration, coma from hyponatremia, secondary hyponatremia due to fluid overload, and hyperammonemia with resultant coma and/or encephalopathy; cardiovascular disorders such as hypotension, tachycardia, angina-like pains; pulmonary disorders such as pulmonary congestion; and other general reactions such as blurred vision, convulsions, nausea, vomiting, rhinitis, chills, vertigo, backache, transient blindness and urticaria. allergic reactions from glycine are unknown or exceedingly rare. should adverse reactions occur, discontinue the irrigation and re-evaluate the clinical status of the patient.
post-marketing experience following off-label use of 1.5% glycine irrigation, usp for hysteroscopic procedures in women, life-threatening adverse events related to fluid overload have been reported.

Use in Pregnancy:

Pregnancy teratogenic effects animal reproduction studies have not been conducted with 1.5% glycine irrigation, usp. it is not known whether 1.5% glycine irrigation, usp can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. 1.5% glycine irrigation, usp should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use safety and effectiveness in pediatric patients have not been established.

Geriatric Use:

Geriatric use clinical studies of irrigation solutions did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from other younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. do not administer unless the solution is clear and the seal is intact.

Overdosage:

Overdosage in the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. see warnings, precautions and adverse reactions.

Description:

Description 1.5% glycine irrigation, usp is a sterile, nonpyrogenic, nonhemolytic, nonelectrolytic or very weakly ionized solution in single dose uromatic containers for use as a urologic irrigating solution. each liter contains 15 g glycine, usp (nh 2 ch 2 cooh) in water for injection. ph 6.0 (4.5 to 6.5). osmolarity 200 mosmol/l (calc.). normal physiologic osmolarity range is approximately 280 to 310 mosmol/l. no antimicrobial agent has been added. the uromatic plastic container is fabricated from a specially formulated polyvinyl chloride (pl 146 plastic). the amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (dehp), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to usp biological tests for plastic containers as well as by tissue culture toxicity studies.

Clinical Pharmacology:

Clinical pharmacology 1.5% glycine irrigation, usp is useful as an irrigating solution for the urinary bladder because this solution is nonhemolytic, nonelectrolytic or very weakly ionized, and provides a high degree of visibility for urologic procedures requiring endoscopy. during transurethral surgical procedures, the solution acts as a lavage for removing blood and tissue fragments. it also maintains the patency of an indwelling catheter in the immediate postoperative period. glycine which enters the systemic circulation is converted to serine and glyoxylic acid.

How Supplied:

How supplied 1.5% glycine irrigation, usp in uromatic plastic containers is available as follows: 2b7317 3000ml ndc 0338-0289-47 color variation in this product is normal and does not alter efficacy or visualization during tur procedures. exposure of pharmaceutical products to heat should be minimized. avoid excessive heat. it is recommended the product be stored at room temperature (25°c); brief exposure up to 40°c does not adversely affect the product. directions for use tear overwrap down side at slit and remove solution container. visually inspect the container. if the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. check for minute leaks by squeezing bag firmly. if leaks are found, discard solutio
n as sterility may be impaired. use aseptic technique. 1. suspend container using hanger hole. 2. remove protector from outlet port. 3. attach irrigation set. refer to complete directions accompanying set. baxter healthcare corporation deerfield, il 60015 usa printed in usa 07-19-00-0226 rev. january 2018 baxter and uromatic are trademarks of baxter international inc.

Package Label Principal Display Panel:

Package label.principal display panel 1.5% glycine irrigation usp container label 1.5% glycine irrigation usp container label lot exp 3000 ml 2b7317 not for injection ndc 0338-0289-47 1.5% glycine irrigation usp each 100 ml contains 1.5g glycine usp no antimicrobial agent has been added ph 6.0 (4.5 to 6.5) hypotonic osmolarity 200 mosmol/l (calc) sterile nonpyrogenic single dose container do not use unless solution is clear discard unused portion irrigating solution for use in urological procedures and cystoscopic examinations see direction sheet color variation in this product is normal and does not alter efficacy or visualization during tur procedures cautions squeeze and inspect inner bag which maintains product sterility discard if leaks are found rx only store unit in moisture barrier overwrap at room temperature (25°c) until ready to use avoid excessive heat see insert 1.5% glycine irrigation usp uromatic container pl 146 plastic baxter logo baxter healthcare corporation deerfield il 60015 usa made in usa baxter uromatic and pl 146 are trademarks of baxter international inc for product information 1-800-933-0303 glycine representative container label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.